Aethlon Medical Inc., a medical therapeutic company focused on developing products for cancer and life-threatening infectious diseases, has announced the publication of preclinical data showcasing the Hemopurifier®'s ability to remove platelet-derived extracellular vesicles (PD-EVs) from plasma. This breakthrough supports their ongoing oncology clinical trial in Australia, as PD-EVs are known to contribute to the spread of cancer. The study, published on bioRxiv, highlights the Hemopurifier's potential across multiple indications, suggesting a "pipeline within a device" approach for future therapeutic applications. Aethlon Medical plans to submit these findings to a peer-reviewed journal and further investigate PD-EV removal in diseases of interest.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.